The Global Pulmonary
Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2
Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma
& COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic
Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and e-Commerce), and by Region (North America, Latin America,
Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 28,064.5
million in 2016 and is projected to exhibit a CAGR of 8.1% over the forecast
period (2017 – 2025).
The pulmonary drugs market is
expected to gain significant traction with patent expiry of branded drugs,
which is expected to generate opportunities for the market players and robust
number of drug candidates in the pipeline as a result of extensive R&D.
Increasing prevalence of
respiratory diseases is expected to propel growth of the market Increasing
prevalence of chronic obstructive pulmonary diseases and other respiratory
diseases across the world is one of the leading causes of death and disability.
Thus, the prevention, treatment, and control of these diseases is one of the
top priorities for governments and players in the healthcare sector. According
to the Forum of International Respiratory Societies, in 2016, around 65 million
people were suffering from chronic obstructive pulmonary disease worldwide,
leading to 3 million deaths. Moreover, around 334 million people suffered from
asthma, which is the most common chronic respiratory condition among children
as well as adults. A wide range of conditions are included within the ambit of
pulmonary diseases that include pneumonia, allergic rhinitis, pulmonary
hypertension, and others that are responsible for creating a giant economic
burden on the healthcare sectors of most of nations. Pulmonary drugs are
focused towards providing medications for all these types of diseases leading
to expected market growth in near future. According to the World Health
Organization, 2017, Chronic Obstructive Pulmonary Diseases (COPD) is
responsible for about 5% of the total deaths worldwide in 2015.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1285
Furthermore, according to the
Office of Disease Prevention and Health Promotion 2014, 25 million patients in
the U.S. had asthma that led to an estimated annual expenditure for asthma
turning around to US$ 20.7 billion. Thus, the constant rise in the number patients
suffering with respiratory diseases are expected to surge the market growth
over the forecast period.
Browse 50 Market Data Tables and
38 Figures spread through 304 Pages and in-depth TOC on “Pulmonary Drugs Market”-
Global Forecast to 2025.
The major manufacturers are
focused towards development of new and innovative products with extensive
R&D on pulmonary drugs. For instance, in 2017, Sanofi SA completed the
phase II clinical trials in April 2017 of new drug Dupilumab in association with
Regeneron Pharmaceuticals. The drug is indicated for the treatment of
uncontrolled asthma in children and is expected to complete its clinical trial
studies in January, 2021. Moreover, in 2017, Circassia Pharmaceuticals
completed Phase IV clinical trials of Tudorza with a collaborative agreement
between Circassia and AstraZeneca Plc. for the treatment of COPD. The key
players adopt the strategies of mergers, definitive agreements, and
acquisitions to expand the respiratory drugs product portfolio, thereby increasing
market share. For instance, in 2015, AstraZeneca Plc entered into a definitive
agreement with Takeda Pharmaceutical Company Limited, under which AstraZeneca
acquired the core respiratory business of Takeda to strengthen respiratory
therapeutic portfolio. Furthermore, in 2016, Mylan N.V. acquired Meda
Pharmaceuticals to enhance geographic reach with significant sales of products
worldwide, in which China, South East Asia, and Middle East were the major regional
targets for the company.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/pulmonary-drugs-market-1285
Key Takeaways of the Pulmonary
Drugs Market:
The global pulmonary drugs market
is expected to exhibit a CAGR of 8.1% over the forecast period, owing to the
presence of high potential market and increasing prevalence of chronic
respiratory diseases in Asia Pacific, Latin America, the Middle East, and
Africa
Among drug class, inhaled
corticosteroids segment holds a dominant position attributed to the advantages
offered by the drugs that include lower concentration of drug delivery into the
patient’s system allowing even distribution as well as lower risk of side
effects that are usually exhibited by oral steroid consumption
Among application, asthma and
COPD segment holds a dominant position in the pulmonary drugs market, owing to
the rising incidence of the condition worldwide.
Some of the major players
operating in the global pulmonary drugs market include Sanofi SA, Meda
Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc.,
GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici
S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1285
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment